#WeWontRest in the fight against COVID-19
The COVID-19 pandemic is the public health challenge of our time. It demands a concerted effort and bold, new thinking to find solutions together. As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak.
#WeWontRest until there is a COVID-19 vaccine for everyone
Vaccines represent our best hope of moving out from under the shadow of the COVID-19 pandemic. Our members are working around the clock to develop a safe and effective COVID-19 vaccine.
A global pandemic demands a fast response: researchers are speeding up the process by conducting phases of development in parallel and by scaling up manufacturing at risk. We’re working with the R&D community, health authorities, regulatory agencies and funding bodies to accelerate efforts, whilst making no compromises in high safety and efficacy standards.
Vaccine developers' top priority is always safety and that is no different for COVID-19 vaccines.
No one is safe until everyone is safe. It's why #WeWontRest in developing and delivering COVID-19 vaccines, to protect our loved ones and millions of people around the world. It is why we are #TeamVaccines.
For more information on vaccines, you can visit the Vaccines Europe website.
IMI carries the torch of medical innovation
EFPIA members are heavily engaged in the Innovative Medicines Initiative (Call 21) to fast track collaborative research, identifying any suitable assets in their libraries that could be utilised to develop diagnostics and treatments in the fight against COVID-19.
The IMI CARE (Corona Accelerated R&D in Europe) project is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19. The CARE consortium will accelerate COVID-19 R&D by bringing together the leading expertise and projects of 37 teams from academic and non-profit research institutions and pharmaceutical companies into a comprehensive drug discovery engine.